The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
대표청구항▼
1. A method for activating an antigen presenting cell, which comprises: transfecting or transducing an antigen presenting cell in vitro or ex vivo with a nucleic acid having a nucleotide sequence that encodes a chimeric protein, wherein the chimeric protein comprises a membrane targeting region, a m
1. A method for activating an antigen presenting cell, which comprises: transfecting or transducing an antigen presenting cell in vitro or ex vivo with a nucleic acid having a nucleotide sequence that encodes a chimeric protein, wherein the chimeric protein comprises a membrane targeting region, a multimerizing region and a CD40 polypeptide cytoplasmic region wherein the CD40 polypeptide does not have a functional extracellular domain; and contacting the antigen presenting cell with a ligand that binds to the multimerizing region resulting in multimerization, whereby the antigen presenting cell is activated. 2. The method of claim 1, wherein the membrane targeting region is selected from the group consisting of a myristoylation region, palmitoylation region, prenylation region, and transmembrane sequences of receptors. 3. The method of claim 1, wherein the multimerizing region is selected from the group consisting of FKBP, cyclophilin receptor, the steroid receptor, the tetracycline receptor, heavy chain antibody subunit, light chain antibody subunit, and mutated sequences thereof. 4. The method of claim 1, wherein the multimerizing region is selected from the group consisting of FKBP, gyrase B, and cyclophilin receptor. 5. The method of claim 1, wherein the nucleic acid is contained within a viral vector. 6. The method of claim 5, wherein the viral vector is an adenoviral vector. 7. The method of claim 1, wherein the antigen presenting cell is a dendritic cell. 8. The method of claim 1, wherein the nucleotide sequence is operably linked to a promoter. 9. The method of claim 1, wherein the nucleic acid is contained within a plasmid. 10. A composition which comprises a nucleic acid having a nucleotide sequence that encodes a chimeric protein, wherein the chimeric protein comprises a membrane targeting region, a multimerizing region and a CD40 polypeptide cytoplasmic region wherein the CD40 polypeptide does not have a functional extracellular domain. 11. The composition of claim 10, wherein the nucleic acid is contained within a viral vector. 12. The composition of claim 11, wherein the viral vector is an adenoviral vector. 13. The composition of claim 10, wherein the nucleic acid comprises a promoter sequence operably linked to the polynucleotide sequence. 14. The composition of claim 10, wherein the nucleic acid is contained within a plasmid. 15. A method for inducing an immune response against an antigen, which comprises transfecting or transducing an antigen presenting cell in vitro or ex vivo with a nucleic acid having a nucleotide sequence that encodes a chimeric protein, wherein the chimeric protein comprises a membrane targeting region, a multimerizing region and a CD40 polypeptide cytoplasmic region wherein the CD40 polypeptide does not have a functional extracellular domain; contacting the antigen presenting cell with an antigen ex vivo or in vitro; contacting the antigen presenting cell with a ligand that binds to the multimerizing region resulting in multimerization; and contacting the antigen presenting cell with a T-cell; whereby an immune response against the antigen is induced. 16. The method of claim 15, wherein the immune response is a cytotoxic T-lymphocyte (CTL). immune response. 17. The method of claim 15, wherein the immune response is generated against a tumor antigen. 18. The method of claim 15, wherein the nucleic acid is contained within a viral vector. 19. The method of claim 18, wherein the viral vector is an adenoviral vector. 20. The method of claim 15, wherein the antigen presenting cell is a dendritic cell. 21. The method of claim 15, wherein the nucleotide sequence is operably linked to a promoter. 22. The method of claim 15, wherein the nucleic acid is contained within a plasmid. 23. The method of claim 15, which comprises administering the antigen presenting cell to a subject. 24. The method of claim 23, wherein the antigen presenting cell is administered to the subject by intradermal administration. 25. The method of claim 23, wherein the antigen presenting cell is administered to the subject by subcutaneous administration. 26. The method of claim 15, wherein the antigen presenting cell is contacted with the ligand before the antigen presenting cell is contacted with the T-cell. 27. The method of claim 23, wherein the antigen presenting cell is contacted with the ligand after the antigen presenting cell is administered to the subject. 28. A method for inducing an immune response against an antigen in vivo, which comprises administering to a subject by a propelling force a composition that includes particles, a nucleotide sequence encoding a chimeric protein and a nucleotide sequence encoding an antigen, wherein the chimeric protein comprises a membrane targeting region, a multimerizing region and a CD40 polypeptide cytoplasmic region wherein the CD40 polypeptide does not have a functional extracellular domain, and whereby an immune response is induced against the antigen. 29. The method of claim 28, wherein the particles are gold particles. 30. The method of claim 28, which further comprises administering a ligand that binds to the multimerizing region resulting in multimerization. 31. The method of claim 28, wherein the nucleic acid is contained within a viral vector. 32. The method of claim 31, wherein the viral vector is an adenoviral vector. 33. The method of claim 28, wherein the propelling force is an electrical current. 34. The method of claim 28, wherein the immune response is a cytotoxic T-lymphocyte (CTL) immune response. 35. The method of claim 28, wherein the antigen is a tumor antigen. 36. The method of claim 28, wherein the nucleotide sequence is operably linked to a promoter. 37. The method of claim 28, wherein the nucleotide sequence encoding the antigen and the nucleotide sequence encoding the chimeric protein are in plasmid DNA. 38. The method of claim 1, wherein the antigen presenting cells are transfected or transduced with a nucleic acid having a nucleotide sequence that encodes a tumor antigen. 39. The method of claim 38, wherein the tumor antigen is PSMA. 40. The method of claim 38, wherein the nucleic acid having a nucleotide sequence that encodes the chimeric protein further comprises a nucleotide sequence that encodes the tumor antigen.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (35)
Wang Rong-Fu ; Rosenberg Steven A., Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein.
Marchand Claudine (Paris FRX) Druilhe Pierre (Saint Mande FRX) Puijalon-Mercereau Odile (Issy Les Moulineaux FRX) Langsley Gordon (Paris FRX), Antibodies which bind to molecules containing at least one peptide sequence carrying one or several epitopes characteris.
Capon Daniel J. ; Tian Huan ; Smith Douglas H. ; Winslow Genine A. ; Siekevitz Miriam, Chimeric receptors comprising janus kinase for regulating cellular pro liferation.
Fikes John D. ; Livingston Brian D. ; Sette Alessandro D. ; Sidney John C., DNA encoding MAGE-1 C-terminal cytotoxic t lymphocyte immunogenic peptides.
Eberlein Timothy J. (Dover MA) Peoples George E. (Newtonville MA) Yoshino Ichiro (Brookline MA) Goedegebuure Peter (Brighton MA), Isolated antigenic oncogene peptide fragments and uses.
Van den Eynde Benoit (Brussels BEX) DeBacker Olivier (Brussels BEX) Boon-Falleur Thierry (Brussels BEX), Isolated peptides derived from tumor rejection antigens, and their use.
Braatz James A. (Beltsville MD) McIntire Kenneth R. (Kensington MD) Princler Gerald L. (Frederick MD), Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection an.
Adams Thomas R. (No. Stonington CT) Chambers Sheryl A. (Groton CT) Daines Richard J. (Ledyard CT) Gordon-Kamm William J. (Stonington CT) Kausch Albert P. (Stonington CT) Lemaux Peggy G. (Mystic CT) M, Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof.
Chang Yin-Fu (Carrboro NC) Wong James R. (Milpitas CA) Itano Andrea (Berkley CA) Mejza Stephen J. (Union City CA) Walker Leslie (Littleton CO), Methods for stable transformation of wheat.
Caldwell Harlan D. ; Ying Yuan ; Zhang You-Xun ; Watkins Nancy G., Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trach.
Crabtree Gerald R. ; Schreiber Stuart L. ; Spencer David M. ; Wandless Thomas J. ; Belshaw Peter, Regulated transcription of targeted genes and other biological events.
Crabtree Gerald R. ; Schreiber Stuart L. ; Spencer David M. ; Wandless Thomas J. ; Belshaw Peter, Regulated transcription of targeted genes and other biological events.
Crabtree Gerald R. ; Schreiber Stuart L. ; Spencer David M. ; Wandless Thomas J. ; Belshaw Peter, Regulated transcription of targeted genes and other biological events.
Crabtree Gerald R. ; Schreiber Stuart L. ; Spencer David M. ; Wandless Thomas J. ; Belshaw Peter ; Ho Steffan, Regulated transcription of targeted genes and other biological events.
Crabtree Gerald R. ; Schreiber Stuart L. ; Spencer David M. ; Wandless Thomas J. ; Belshaw Peter ; Ho Steffan N., Regulated transcription of targeted genes and other biological events.
Crabtree Gerald R. ; Schreiber Stuart L. ; Spencer David M. ; Wandless Thomas J. ; Ho Steffan N. ; Belshaw Peter, Regulated transcription of targeted genes and other biological events.
Spencer, David; Narayanan, Priyadharshini, Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters.
Spencer, David; Narayanan, Priyadharshini, Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters.
Spencer, David; Narayanan, Priyadharshini, Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters.
Bermudes, David Gordon, Protease inhibitor: protease sensitive expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria.
Bermudes, David Gordon; Quintero, David, Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.